New immunotherapy combo shows promise for Hard-to-Treat cancers

NCT ID NCT05024214

Recruiting now Disease control Sponsor: 3D Medicines (Sichuan) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatment will receive the combo. The goal is to see if more tumors respond compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Envafolimab (an immunotherapy drug) and Lenvatinib (a targeted cancer drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply broadly. The drugs can cause side effects like fatigue, high blood pressure, and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma neoplasm non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NON-SMALL CELL LUNG CANCER RENAL CELL CARCINOMA SOLID TUMORS

Contacts and locations

Locations

Beijing Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100730, China
Dongguan People's Hospital
RECRUITING

Dongguan, Guangdong, 523059, China
First Hospital of Shanxi Medical University
RECRUITING

Taiyuan, Shanxi, 030001, China
Fudan University
RECRUITING

Shanghai, China
Fujian Medical University Union Hospital
NOT_YET_RECRUITING

Fuzhou, Fujian, 350001, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Haerbin, Heilongjiang, 150081, China
Jilin Cancer Hospital
NOT_YET_RECRUITING

Changchun, Jilin, 130028, China
Liaoning Cancer Hospital & Institute
RECRUITING

Shenyang, Liaoning, 110011, China
Shengjing Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110001, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310020, China
THE First Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, 130012, China
The 960th Hospital of the PLA Joint Logistics Support Force
RECRUITING

Jinan, Shandong, 250031, China
The Cancer Affiliated Hospital of Xinjiang Medical College
RECRUITING

Ürümqi, Xinjiang, 830011, China
The Fifth Affiliated Hospital Sun Yat-Sen University
RECRUITING

Zhuhai, Guangdong, 519000, China
The First Affiliated Hospital of Bengbu Medical College
RECRUITING

Bengbu, Anhui, 233004, China
The First Affiliated Hospital of Dalian Medical University
RECRUITING

Dalian, Liaoning, 116011, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450052, China
The Second Affiliater Hospital of Nanchang University
NOT_YET_RECRUITING

Nanchang, Jiangxi, 330006, China
The Seventh Medical Center of the PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100700, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China
Yunnan Cancer Hospital
RECRUITING

Kunming, Yunnan, 650118, China
Zhongshan Hospital,Fudan University(Xiamen Branch)
NOT_YET_RECRUITING

Xiamen, Fujian, 361015, China
Zhujiang Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.